|
1
|
Wahlgren T, Harmenberg U, Sandström P,
Lundstam S, Kowalski J, Jakobsson M, Sandin R and Ljungberg B:
Treatment and overall survival in renal cell carcinoma: A Swedish
population-based study (2000-2008). Br J Cancer. 108:1541–1549.
2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Motzer RJ, Tannir NM, McDermott DF, Arén
Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P,
Porta C, George S, et al: Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma. N Engl J Med.
378:1277–1290. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tannir NM, Plimack E, Ng C, Tamboli P,
Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, et al: A
phase 2 trial of sunitinib in patients with advanced non-clear cell
renal cell carcinoma. Eur Urol. 62:1013–1019. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lee JL, Ahn JH, Lim HY, Park SH, Lee SH,
Kim TM, Lee DH, Cho YM, Song C, Hong JH, et al: Multicenter phase
II study of sunitinib in patients with non-clear cell renal cell
carcinoma. Ann Oncol. 23:2108–2114. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Matrana MR, Baiomy A, Campbell M, Alamri
S, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, et
al: Outcomes of patients with metastatic non-clear-cell renal cell
carcinoma treated with pazopanib. Clin Genitourin Cancer.
15:e205–e208. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Jung KS, Lee SJ, Park SH, Lee JL, Lee SH,
Lim JY, Kang JH, Lee S, Rha SY, Lee KH, et al: Pazopanib for the
treatment of non-clear cell renal cell carcinoma: A single-arm,
open-label, multicenter, phase II study. Cancer Res Treat.
50:488–494. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Park I, Lee SH and Lee JL: A multicenter
phase II trial of axitinib in patients with recurrent or metastatic
non-clear-cell renal cell carcinoma who had failed prior treatment
with temsirolimus. Clin Genitourin Cancer. 16:e997–e1002.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Moch H, Humphrey PA, Ulbright TM and
Reuter VE: WHO classification of tumours of the Urinary System and
Male Genital Organs. Lyon: IARCPress, 2016.
|
|
9
|
Mejean A, Hopirtean V, Bazin JP,
Larousserie F, Benoit H, Chrétien Y, Thiounn N and Dufour B:
Prognostic factors for the survival of patients with papillary
renal cell carcinoma: Meaning of histological typing and
multifocality. J Urol. 170:764–767. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ravaud A, Oudard S, De Fromont M, Chevreau
C, Gravis G, Zanetta S, Theodore C, Jimenez M, Sevin E, Laguerre B,
et al: First-line treatment with sunitinib for type 1 and type 2
locally advanced or metastatic papillary renal cell carcinoma: A
phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
Ann Oncol. 26:1123–1128. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Dutcher JP, de Souza P, McDermott D,
Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold
J and Hudes G: Effect of temsirolimus versus interferon-α on
outcome of patients with advanced renal cell carcinoma of different
tumor histologies. Med Oncol. 26:202–209. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Armstrong AJ, Halabi S, Eisen T, Broderick
S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J,
Hawkins RE, et al: Everolimus versus sunitinib for patients with
metastatic non-clear cell renal cell carcinoma (ASPEN): A
multicentre, open-label, randomised phase 2 trial. Lancet Oncol.
17:378–388. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tannir NM, Jonasch E, Albiges L,
Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z,
Tamboli P, et al: Everolimus versus sunitinib prospective
evaluation in metastatic non-clear cell renal cell carcinoma
(ESPN): A randomized multicenter phase 2 trial. Eur Urol.
69:866–874. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ito K, Mikami S, Tatsugami K, Masumori N,
Shinohara N, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, et
al: Clinical outcomes in patients with metastatic papillary
renal-cell carcinoma: A multi-institutional study in Japan. Clin
Genitourin Cancer. 16:e1201–e1214. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mori J, Nakayama Y, Hiragino T and
Matsuyama H: Successful treatment of peritoneal dissemination
recurrence with axitinib in papillary renal cell carcinoma: A case
report. Hinyokika Kiyo. 64:45–48. 2018.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
16
|
Ishii G, Hatano T, Endo K, Seki K, Yamada
H, Kimura T and Egawa S: A case of papillary renal cell carcinoma
type 2 resistant to sunitinib responded to second line therapy with
axitinib. Nihon Hinyokika Gakkai Zasshi. 105:129–133.
2014.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
17
|
Mukohara T, Nakajima H, Mukai H, Nagai S,
Itoh K, Umeyama Y, Hashimot J and Minami H: Effect of axitinib
(AG-013736) on fatigue, thyroid-stimulating hormone, and
biomarkers: A phase I study in Japanese patients. Cancer Sci.
101:963–968. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Arai Y, Ito K, Tachi K, Koga A, Shinchi Y,
Masunaga A, Isono M and Asano T: Metastatic renal cell carcinoma in
paranasal sinus for which periodic drug withdrawal schedule of
axitinib was effective: A case report. Hinyokika Kiyo. 62:465–471.
2016.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
19
|
Takayama T, Nagata M, Kai F, Sugiyama T
and Ozono S: Axitinib controlled metastatic renal cell carcinoma
for 5 years. Jpn J Clin Oncol. 43:747–751. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Margulis V, Tamboli P, Matin SF, Swanson
DA and Wood CG: Analysis of clinicopathologic predictors of
oncologic outcome provides insight into the natural history of
surgically managed papillary renal cell carcinoma. Cancer.
112:1480–1488. 2008.PubMed/NCBI View Article : Google Scholar
|
